By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Am Klopferspitz 19a

Martinsried    82152  Germany
Phone: 49-0-89-7007630 Fax: 49-0-89-700763-29



Company News
New Mechanistic Insights Into 4SC (VSC.F)-202's Epigenetic Mode Of Action 4/14/2017 8:25:40 AM
4SC (VSC.F) Release: Overall Survival Benefit For Resminostat In First-Line Liver Cancer Study Subgroup 1/26/2017 9:41:42 AM
Guangzhou Link Health In $85 Million Deal For Cancer Drug From 4SC AG (VSC.F) 6/1/2016 8:38:10 AM
4SC AG (VSC.F) Sells Operations Of Its Discovery Division 4/29/2016 9:45:09 AM
4SC AG (VSC.F) in Talks With 3 Potential Partners for Cancer Drug 9/13/2012 8:00:37 AM
4SC AG (VSC.F) Says Its Resminostat Meets Primary Endpoint In Phase II Trial 1/19/2012 11:00:19 AM
4SC AG (VSC.F)'s Anti-Cancer Compound Resminostat Receives Positive Opinion for Orphan Medicinal Product Designation in Europe to Treat Hodgkin's Lymphoma 10/13/2011 10:21:46 AM
4SC AG (VSC.F)'s Resminostat receives FDA Orphan Drug Status for Hodgkin's Lymphoma 9/26/2011 9:36:52 AM
4SC AG (VSC.F)'s Resminostat Meets Primary Efficacy Endpoint in Phase II Trial in Hodgkin's Lymphoma (HL) 9/6/2011 6:46:24 AM
FDA Grants Orphan Drug Designation to 4SC AG (VSC.DU)'s Oral Pan-HDAC Inhibitor Resminostat for the Treatment of Hepatocellular Carcinoma 7/12/2011 9:47:27 AM